Trial
NCT01032070
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
OSI Pharmaceuticals
Collaborators
—
Condition
Recurrent or Refractory Pediatric Ependymoma
Intervention
erlotinib
Why stopped
In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, it has been stopped.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-12